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In human medicine there have been many studies reporting the
importance of evaluating serum ET-1 or big ET-1 in various diseases
as a clinical marker, especially related to pulmonary hypertension
and several tumors. In veterinary medicine, however, few studies
have been performed on the clinical importance of serum ET-1 or
big ET-1. In this study we explored the feasibility of using the serum
big ET-1 as a clinical marker in dogs with various cardiopulmonary
and neoplastic diseases. Pulmonary hypertension was diagnosed in
dogs by echocardiography based on the velocity of tricuspid valve
regurgitation. Serum big ET-1 and NT-pro BNP concentrations in these
dogsweremeasuredby ELISA and comparedwith those of healthy dogs.
Serum big ET-1 concentration in dogs with various neoplastic diseases
was also assessed and compared. Our results showed a signiﬁcant
increase of serum big ET-1 in dogs with pulmonary hypertension,
lung tumor and hemangiosarcoma when compared to normal dogs.
No signiﬁcant difference was observed in NT-pro BNP concentration
between healthy and pulmonary hypertension dogs. Although further
studies are necessary, these ﬁndings point to the potential of serum big
ET-1 as a clinical marker in canine pulmonary hypertension and for
some tumor types.
doi:10.1016/j.lfs.2013.12.050
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A 56-year-old man developed sudden dyspnoea after resection of
choroidal melanoma in his left eyeball. Worsening hypoxia required
intensive treatment, including percutaneous cardiopulmonary support.
On contrast-enhanced computed tomography there was no evidence
of either thrombi in the pulmonary arteries or obvious lung diseases.
A Swan–Ganz catheter showed increased mean pulmonary arterial
pressure and no elevation of pulmonary capillary wedge pressure.
These ﬁndings were consistent with a diagnosis of pulmonary arterial
hypertension. Because reports have described a signiﬁcant relation-
ship between melanoma and endothelin (ET)-1, we hypothesized that
a substantial amount of ET-1 had been released from malignant mela-
noma cells during resection, thus triggering the pulmonary hyperten-
sive crisis in our patient. The patient fully recovered after intensive
treatment and administration of the endothelin receptor antagonist
bosentan. The success of bosentan treatment, along with an extremely
high level of ET-1 on pathologic analysis, conﬁrmed our hypothesis
regarding an increase in plasma ET-1 level — 9.60 pg/mL (normal
range b 2.3 pg/mL).
doi:10.1016/j.lfs.2013.12.051
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Objective: The primary objective of the Phase I study was to assess
the safety and tolerability of SPI-1620 administered to patients with
recurrent or progressive carcinomawhohad failed all standard therapy.
Secondary objectives were to assess PK and PD proﬁles of SPI-1620,
and to identify the optimum dose of SPI-1620 to be used in future
Phase II studies. The pharmacokinetic properties of SPI-1620 will be
presented. Methods: Eligible patients received SPI-1620 by intravenous
infusion over 1 min in an accelerated dose escalation scheme. SPI-1620
doses ranged from 0.5 μg/m2 to 15.1 μg/m2. Serial blood samples were
collected from each patient prior to infusion (0 min) and at pre-
speciﬁed intervals from the start of the infusion. Human plasma
samples were analyzed by a validated HPLC–MS/MS method. Descrip-
tive PK parameters were determined by standard model independent
methods based on the concentration–time data of each subject. Results
& conclusion: The highest concentration of SPI-1620 was achieved
by the end of infusion. SPI-1620 C max increased proportionally as a
function of SPI-1620 dosewhile the AUC (0–T) increased in amore than
dose proportional manner. The SPI-1620 T 1/2 was short and ranged
from 4.38 min to 8.29 min. SPI-1620 had a low systemic clearance and
small VD (approximately equal to the intravascular volume).
doi:10.1016/j.lfs.2013.12.052
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The epithelial–mesenchymal transition (EMT) is known to play a
crucial role in the aggressiveness of epithelial ovarian cancer (EOC),
contributing to chemoresistance and cancer stem cell populations. In
this tumor, the endothelin (ET)-1/endothelin A receptor (ETAR) axis,
by regulating EMT and invasion, endows EOC cells with an increased
chemoresistance. Here we examined whether β-arrestin-1 (β-arr1)
can act as a nuclear hub orchestrating nuclear signaling in ETAR-
driven EMT and chemoresistance. A signiﬁcant higher expression of
β-arr1 and ET-1/ETAR and the stronger presence of β-arr1 in the
nuclear compartment upon ETAR activation are present in chemo-
resistant cells, compared to sensitive cells. In the nuclei, β-arr1
robustly interacts with β-catenin to form a nuclear complex localized
on the ET-1 promoter region, leading to transcription of ET-1, dem-
onstrating that β-arr1 drives the positive inter-regulation of ET-1
itself. This autocrine circuit is involved in β-arr1-driven appearance
of EMT features and acquisition of stem-cell like properties. More-
over, at functional level, chemoresistant cells, with high nuclear
β-arr1, display higher invasive potential and increased resistance
to chemotherapeutic drugs. These effects were inhibited by ET-1
receptor blockade with macitentan, or by β-arr1 nuclear mutant.
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Moreover, in vivo, silencing of β-arr1 ormacitentan treatment inhibited
metastasis in sensitive and resistant EOC xenografts, providing evi-
dence that blockade of ETAR/β-arr1-driven EMT can overcome chemo-
resistance and inhibit tumor progression. Collectively, our ﬁndings
provide insights into how ETAR controls EMT transcriptional responses
and tumor initiating trait, deciphering a novel function for β-arr1
for nuclear compartmentalization of ETAR signalling inﬂuencing the
mechanism of acquired resistance, EMT and stem-cell like features.
doi:10.1016/j.lfs.2013.12.053
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The endothelin system is an important paracrine or autocrine
system for cancer cell proliferation. Endothelin-1 and endothelin
receptors are expressed in various types of cancers including breast
cancer. (Pro)renin receptor ((P)RR) is a speciﬁc receptor for renin and
prorenin. Receptor-bound prorenin becomes enzymatically active in
converting angiotensinogen to angiotensin I, and binding then activates
phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2),
independent of angiotensin II generation. Furthermore, (P)RR is asso-
ciated with vacuolar-type H+-ATPase (V-ATPase), which may be
related to cell proliferation. The aim of the present study is to clarify
the pathophysiological role of (P)RR in breast cancer. We investigated
(P)RR expression in 69 clinical cases of breast carcinoma by immuno-
histochemistry and its correlation with clinicopathological parameters.
Effects of (P)RR on cell proliferation and ERK1/2 phosphorylation
were examined in cultured human breast carcinoma cells. Immuno-
histochemistry showed that (P)RR immunoreactivity was detected
in carcinoma cells of breast carcinoma tissues, and was correlated
with Ki-67 expression. The (P)RR speciﬁc small interference RNA or
baﬁlomycin A1 (an inhibitor of V-ATPase activity) inhibited cell growth
of breast carcinoma cell lines (MCF-7 and SK-BR-3). Prorenin stimulat-
ed the phosphorylation of ERK1/2 in MCF-7 cells. Treatment of MCF-7
cells with endothelin-1 had no signiﬁcant effects on (P)RR expression
levels. The present study has raised the possibility that, in addition
to the endothelin system, (P)RR is involved in the pathophysiology of
breast cancer by stimulating the proliferation of breast carcinoma cells
via the association of V-ATPase and/or phosphorylation of ERK1/2.
doi:10.1016/j.lfs.2013.12.054
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Poly-gamma-glutamic acid (PGA), naturally secreted from various
strains of Bacillus, has anti-inﬂammatory activity. In inﬂammatory
bowel disease (IBD), inﬂammation is promoted and sustained by
angiogenesis; however, the role played by PGA in this condition is
unclear. Therefore, we evaluated PGA effects on angiogenesis and
inﬂammation in a dextran sulfate sodium (DSS)-induced mouse
colitis model. Experimental colitis was induced in male C57BL/6 mice
by administering 3% DSS. Disease activity index (DAI), histopatho-
logical scores, microvascular density, myeloperoxidase activity, and
VEGF-A and VEGFR2 expression were compared among control mice,
DSS-treated mice, and mice receiving 3% DSS along with PGA at
50 mg/kg body weight per day, or 3% DSS with PGA at 200 mg/kg
body weight per day. We found that PGA signiﬁcantly attenuated
weight loss, DAI, and colon shortening. PGA also signiﬁcantly re-
duced histopathological evidence of injury. Moreover, PGA signiﬁ-
cantly attenuated DSS-induced blood vessel densities. Furthermore,
PGA attenuated DSS-induced expression of VEGF-A and its receptor,
VEGFR2. In addition, PGA treatment led to reduced recruitment of
leukocytes to the inﬂamed colon. Therefore, our results indicate that
PGA has potential application in conditions marked by inﬂammatory-
driven angiogenesis and mucosal inﬂammation.
doi:10.1016/j.lfs.2013.12.055
Identiﬁcation of bladder endothelin-1 receptors and binding
characteristics of bosentan and ambrisentan
Ayaka Osano
Pharmacokinetics and Pharmacodynamics, Japan
Clinical Pharmacology and Genetics, Japan
E-mail address: s12134@u-shizuoka-ken.ac.jp (A. Osano)
Endothelin (ET)-1 induces prolonged contractile responses in
isolated bladder muscle strips. ET-like immunoreactivity was identiﬁed
in detrusor muscles, epithelium and vascular endothelium. Selective
ETA receptor antagonists have ameliorating effects on urinary dysfunc-
tions. The current study aimed to identify bladder ET-1 receptors using
radioligand binding assay and characterize receptor binding of clinically
used ET-1 receptor antagonists. ET-1 receptors were measured in
rat bladder using [125I]ET-1, and binding parameters of dissociation
constant (Kd), and the maximal number of binding sites (Bmax) for
[125I]ET-1were estimated. The inhibition of speciﬁc [125I]ET-1 binding
was measured in the presence of ET-1 and its receptor antagonists.
Speciﬁc [125I]ET-1 binding in rat bladder was saturable and of high
afﬁnity, which characterized selective labeling of bladder ET-1 recep-
tors. ET-1, bosentan, ambrisentan, and CI-1020 inhibited speciﬁc [125I]
ET-1 binding in a concentration-dependent manner at nanomolar
ranges of IC50. Nonlinear least squares regression analysis revealed the
presence of high- and low-afﬁnity ET-1 receptor sites for ambrisentan
and CI-1020. Bosentan signiﬁcantly increased Kd for bladder [125I]ET-1
binding without affecting Bmax, while ambrisentan increased Kd
with a concomitant reduction in Bmax. Thus, bosentan seems to bind
bladder ET-1 receptor in a competitive and reversible manner while
ambrisentan may bind to bladder ET-1 receptors, partially in a non-
competitive manner in addition to a competitive manner. Oral admin-
istration of bosentan caused a dose-dependent decrease in Bmax for
bladder [125I]ET-1 binding, suggesting signiﬁcant binding of bladder
ET-1 receptors in vivo. These results indicate that pharmacologically
relevant ET-1 receptors exist in rat bladder and they may become a
promising target for the development of novel therapeutic agents for
bladder dysfunction.
doi:10.1016/j.lfs.2013.12.056
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